Monograph Details
|
|
Immune System
> Immunization
|
|
ROTATEQ |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Pentavalent, live rotavirus vaccine; oral susp; contains fetal bovine serum (trace); preservative- and thimerosal-free. |
| Indications |
|
Rotavirus gastroenteritis vaccination in infants 6–32 weeks of age. |
| Children |
|
<6 weeks or >32 weeks: not recommended. Each dose is 1 tube. Give 1st dose orally at 6–12 weeks of age; give 2nd and 3rd dose at 4–10 week intervals for a total of 3 doses. If incomplete dose is given, do not give replacement dose; continue with remaining doses in the recommended series. |
| Adults |
|
Not recommended. |
| Precautions |
|
Immunocompromised. Febrile illness. Active or history of GI disorders. Chronic diarrhea. Failure to thrive. History of congenital abdominal disorders. Abdominal surgery. Intussusception. Immunodeficient close contacts. |
| Interactions |
|
Immunosuppressants (eg, irradiation, chemotherapy, high-dose steroids): may get suboptimal response. Concomitant vaccines: see literature; oral polio vaccine: not recommended. |
| Adverse Reactions |
|
Diarrhea, vomiting, otitis media, nasopharyngitis, bronchospasm; rare: intussusception, hematochezia, seizures, Kawasaki disease. |
| How Supplied |
|
Single-use tube (2mL)—1, 10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
